Table 5. Most prevalent serotypes in 6 countries reporting Streptococcus pneumoniae type to ICS and proportion of isolates covered by PCV7 and PCV13 vaccines*.
| Rank | Alaska |
Canada |
Greenland, n = 60 | Iceland, n = 269 | Norway, n = 291 | Finland, n = 3,947 | |||
|---|---|---|---|---|---|---|---|---|---|
| Pre-PCV7, 1999–2000, n = 224 | Post-PCV7, 2001–2005, n = 453 | Pre-PCV7, 1999–2002, n = 158 | Post-PCV7, 2003–2005, n = 82 | ||||||
| 1 | 14 (17%) | 19A (11%) | 1 (34%) | 1 (24%) | 1 (22%) | 7 (20%) | 4, 14 (18%) | 14, 4 (12%) | |
| 2 | 4, 7F (9%) | 4 (8%) | 14 (11%) | 8 (11%) | 12F (15%) | 14 (12%) | 9 (11%) | 9V (8%) | |
| 3 | 9V (8%) | 12F (8%) | 4 (9%) | 3 (7%) | 4 (12%) | 23 (12%) | 6 (9%) | 3, 23F, 7F (7%) | |
| 4 | 19F (6%) | 3, 7F, 8 (7%) | 8 (8%) | 10A, 18C, 22F (6%) | 22F (8%) | 19 (10%) | 23 (8%) | 6B (6%) | |
| 5 |
6B (6%) |
14 (6%) |
|
6B, 9V (6%) |
6B (5%) |
3 (7%) |
9 (10%) |
7 (7%) |
19A, 19F (4%) |
| Proportion of serotyped isolates covered by PCV7 and PCV13 vaccines (<2 y of age) | |||||||||
| PCV7 | 82% (51/62) | 21% (16/77) | 76% (25/33) | 21% (3/14) | 50% (3/6) | 51% (23/45) | 37% (10/27) | NA | |
| PCV13 | 92% (57/62) | 57% (44/77) | 94% (31/33) | 43% (6/14) | 83% (5/6) | 60% (27/45) | 56% (15/27) | NA | |
*ICS, International Circumpolar Surveillance; PCV7, 7-valent pneumococcal conjugate vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F); PCV13, 13-valent pneumococcal conjugate vaccine (7 PCV7sero types plus 1, 3, 5, 6A, 7F, and 19A); NA, not available.